Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “calcitonin”

12 pharma patents match "calcitonin" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 12
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 12 pharmaceutical patents matching "calcitonin" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

12 results for “calcitonin” · 30,257 patents in full index Clear search

  1. US 11555064

    Treating headache comprising administering an antibody to calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 17, 2023 · Expires Jan 12, 2043

    granted
  2. US 10723778

    Variants of adrenomedullin and calcitonin gene-related peptide and methods of use

    The Board of Regents of the University of Oklahoma · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted
  3. US 10597448

    Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Mar 24, 2020 · Expires Mar 19, 2040

    granted
  4. US 10556945

    Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 11, 2020 · Expires Feb 6, 2040

    granted
  5. US 10519224

    Treating headache comprising administering an antibody to calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted
  6. US 10464983

    Variants of adrenomedullin and calcitonin gene-related peptide and methods of use

    The Board of Regents of the University of Oklahoma · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  7. US 10329343

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted
  8. US 9896502

    Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 20, 2018 · Expires Feb 15, 2038

    granted
  9. US 9890210

    Antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  10. US 9890211

    Antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  11. US 9884908

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  12. US 9884907

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted